Mind Games | Full Measure

The biggest new hope for a blockbuster drug to cure Alzheimer’s has been mired in controversy ever since it went to market. Critics say it’s a sign of declining standards and conflicts of interest at the FDA. And now, the federal government is set to decide on whether to buy the controversial medicine for Medicare patients. Today, we update a drug that entered the market in one of the most controversial processes ever.

———
Full Measure is a weekly Sunday news program focusing on investigative, original and accountability reporting. The host is Sharyl Attkisson, five-time Emmy Award winner and recipient of the Edward R. Murrow award for investigative reporting. She is backed by a team of award winning journalists.

Each week, we have a cover story that explores untouchable topics in a fearless way including: immigration, terrorism, government waste, national security and whistleblower reports on government and corporate abuse and misdeeds.

Full Measure is broadcast to 43 million households in 79 markets on 162 Sinclair Broadcast Group stations, including ABC, CBS, NBC, FOX, CW, MyTV, Univision and Telemundo affiliates. It also streams live Sunday mornings at 9:30 a.m. ET.

Read more about us at: http://fullmeasure.news/about
Find out where to watch us at: http://fullmeasure.news/about
Like us on Facebook: https://www.facebook.com/FullMeasureNews
Follow us on Twitter: https://twitter.com/FullMeasureNews

This video and all Sinclair Broadcast Group content archives of local news and sports coverage are available for your use. For more information contact us at contentsales@sbgtv.com